<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>3 Chemotherapy Dosage Based on Renal Function | 　　　　</title>
  <meta name="description" content="3 Chemotherapy Dosage Based on Renal Function | 　　　　" />
  <meta name="generator" content="bookdown 0.21 and GitBook 2.6.7" />

  <meta property="og:title" content="3 Chemotherapy Dosage Based on Renal Function | 　　　　" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="3 Chemotherapy Dosage Based on Renal Function | 　　　　" />
  
  
  




  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="chemotherapy-dosage-based-on-hepatic-function.html"/>
<link rel="next" href="dialysis-of-chemotherapy-drugs.html"/>
<script src="libs/header-attrs-2.7/header-attrs.js"></script>
<script src="libs/jquery-3.5.1/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />









<link href="libs/tabwid-1.0.0/tabwid.css" rel="stylesheet" />
<script src="libs/htmlwidgets-1.5.3/htmlwidgets.js"></script>
<link href="libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="libs/datatables-binding-0.17/datatables.js"></script>
<link href="libs/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="libs/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="libs/dt-core-1.10.20/js/jquery.dataTables.min.js"></script>
<link href="libs/nouislider-7.0.10/jquery.nouislider.min.css" rel="stylesheet" />
<script src="libs/nouislider-7.0.10/jquery.nouislider.min.js"></script>
<link href="libs/selectize-0.12.0/selectize.bootstrap3.css" rel="stylesheet" />
<script src="libs/selectize-0.12.0/selectize.min.js"></script>
<link href="libs/dt-plugin-searchhighlight-1.10.20/source.css" rel="stylesheet" />
<script src="libs/dt-plugin-searchhighlight-1.10.20/jquery.highlight.js"></script>
<script src="libs/dt-plugin-searchhighlight-1.10.20/source.min.js"></script>
<link href="libs/crosstalk-1.1.1/css/crosstalk.css" rel="stylesheet" />
<script src="libs/crosstalk-1.1.1/js/crosstalk.min.js"></script>
<script src="libs/es6shim-0.35.6/es6shim.js"></script>
<script src="libs/es7shim-6.0.0/es7shim.js"></script>
<script src="libs/graphre-0.1.3/graphre.js"></script>
<script src="libs/nomnoml-1.3.1/nomnoml.js"></script>
<script src="libs/nomnoml-binding-0.2.3/nomnoml.js"></script>



<link rel="stylesheet" href="css/JhengHei.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="index.html#pharmed"><strong>《pharmed》</strong></a></li>
<li><a href="part-i-chemotherapy.html#part-i---chemotherapy"><em>Part I - Chemotherapy</em></a></li>
<li class="chapter" data-level="1" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html"><i class="fa fa-check"></i><b>1</b> Oncology Performance Status</a>
<ul>
<li class="chapter" data-level="1.1" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html#karnofsky-performance"><i class="fa fa-check"></i><b>1.1</b> Karnofsky Performance</a></li>
<li class="chapter" data-level="1.2" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html#lansky-performance"><i class="fa fa-check"></i><b>1.2</b> Lansky Performance</a></li>
<li class="chapter" data-level="1.3" data-path="oncology-performance-status.html"><a href="oncology-performance-status.html#ecog-performance"><i class="fa fa-check"></i><b>1.3</b> ECOG Performance</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="chemotherapy-dosage-based-on-hepatic-function.html"><a href="chemotherapy-dosage-based-on-hepatic-function.html"><i class="fa fa-check"></i><b>2</b> Chemotherapy Dosage Based on Hepatic Function</a>
<ul>
<li class="chapter" data-level="2.1" data-path="chemotherapy-dosage-based-on-hepatic-function.html"><a href="chemotherapy-dosage-based-on-hepatic-function.html#recommended-dose-reduction-for-hepatic-dysfunction"><i class="fa fa-check"></i><b>2.1</b> Recommended Dose Reduction for Hepatic Dysfunction</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="chemotherapy-dosage-based-on-renal-function.html"><a href="chemotherapy-dosage-based-on-renal-function.html"><i class="fa fa-check"></i><b>3</b> Chemotherapy Dosage Based on Renal Function</a>
<ul>
<li class="chapter" data-level="3.1" data-path="chemotherapy-dosage-based-on-renal-function.html"><a href="chemotherapy-dosage-based-on-renal-function.html#recommended-dose-reduction-for-renal-dysfunction"><i class="fa fa-check"></i><b>3.1</b> Recommended Dose Reduction for Renal Dysfunction</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="dialysis-of-chemotherapy-drugs.html"><a href="dialysis-of-chemotherapy-drugs.html"><i class="fa fa-check"></i><b>4</b> Dialysis of Chemotherapy Drugs</a>
<ul>
<li class="chapter" data-level="4.1" data-path="dialysis-of-chemotherapy-drugs.html"><a href="dialysis-of-chemotherapy-drugs.html#guidelines-for-dialysis-of-chemotherapy-drugs"><i class="fa fa-check"></i><b>4.1</b> Guidelines for Dialysis of Chemotherapy Drugs</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html"><i class="fa fa-check"></i><b>5</b> Common Chemotherapy Regimens</a>
<ul>
<li class="chapter" data-level="5.1" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#adrenocortical-cancer"><i class="fa fa-check"></i><b>5.1</b> ADRENOCORTICAL CANCER</a></li>
<li class="chapter" data-level="5.2" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#anal-cancer"><i class="fa fa-check"></i><b>5.2</b> ANAL CANCER</a></li>
<li class="chapter" data-level="5.3" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#basal-cell-cancer"><i class="fa fa-check"></i><b>5.3</b> BASAL CELL CANCER</a></li>
<li class="chapter" data-level="5.4" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#biliary-tract-cancer"><i class="fa fa-check"></i><b>5.4</b> BILIARY TRACT CANCER</a></li>
<li class="chapter" data-level="5.5" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#bladder-cancer"><i class="fa fa-check"></i><b>5.5</b> BLADDER CANCER</a></li>
<li class="chapter" data-level="5.6" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#brain-cancer"><i class="fa fa-check"></i><b>5.6</b> BRAIN CANCER</a></li>
<li class="chapter" data-level="5.7" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#breast-cancer"><i class="fa fa-check"></i><b>5.7</b> BREAST CANCER</a></li>
<li class="chapter" data-level="5.8" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#cancer-of-unknown-primary"><i class="fa fa-check"></i><b>5.8</b> CANCER OF UNKNOWN PRIMARY</a></li>
<li class="chapter" data-level="5.9" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#carcinoid-tumors-and-neuroendocrine-tumors"><i class="fa fa-check"></i><b>5.9</b> CARCINOID TUMORS AND NEUROENDOCRINE TUMORS</a></li>
<li class="chapter" data-level="5.10" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#cervical-cancer"><i class="fa fa-check"></i><b>5.10</b> CERVICAL CANCER</a></li>
<li class="chapter" data-level="5.11" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#colorectal-cancer"><i class="fa fa-check"></i><b>5.11</b> COLORECTAL CANCER</a></li>
<li class="chapter" data-level="5.12" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#endometrial-cancer"><i class="fa fa-check"></i><b>5.12</b> ENDOMETRIAL CANCER</a></li>
<li class="chapter" data-level="5.13" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#esophageal-cancer"><i class="fa fa-check"></i><b>5.13</b> ESOPHAGEAL CANCER</a></li>
<li class="chapter" data-level="5.14" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#gastric-cancer"><i class="fa fa-check"></i><b>5.14</b> GASTRIC CANCER</a></li>
<li class="chapter" data-level="5.15" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#gastrointestinal-stromal-tumor-gist"><i class="fa fa-check"></i><b>5.15</b> GASTROINTESTINAL STROMAL TUMOR (GIST)</a></li>
<li class="chapter" data-level="5.16" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#head-and-neck-cancer"><i class="fa fa-check"></i><b>5.16</b> HEAD AND NECK CANCER</a></li>
<li class="chapter" data-level="5.17" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#hepatocellular-cancer"><i class="fa fa-check"></i><b>5.17</b> HEPATOCELLULAR CANCER</a></li>
<li class="chapter" data-level="5.18" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#kaposis-sarcoma"><i class="fa fa-check"></i><b>5.18</b> KAPOSI’S SARCOMA</a></li>
<li class="chapter" data-level="5.19" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#leukemia"><i class="fa fa-check"></i><b>5.19</b> LEUKEMIA</a></li>
<li class="chapter" data-level="5.20" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#lung-cancer"><i class="fa fa-check"></i><b>5.20</b> LUNG CANCER</a></li>
<li class="chapter" data-level="5.21" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#lymphoma"><i class="fa fa-check"></i><b>5.21</b> LYMPHOMA</a></li>
<li class="chapter" data-level="5.22" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#malignant-melanoma"><i class="fa fa-check"></i><b>5.22</b> MALIGNANT MELANOMA</a></li>
<li class="chapter" data-level="5.23" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#malignant-mesothelioma"><i class="fa fa-check"></i><b>5.23</b> MALIGNANT MESOTHELIOMA</a></li>
<li class="chapter" data-level="5.24" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#merkel-cell-cancer"><i class="fa fa-check"></i><b>5.24</b> MERKEL CELL CANCER</a></li>
<li class="chapter" data-level="5.25" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#multiple-myeloma"><i class="fa fa-check"></i><b>5.25</b> MULTIPLE MYELOMA</a></li>
<li class="chapter" data-level="5.26" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#myelodysplastic-syndrome"><i class="fa fa-check"></i><b>5.26</b> MYELODYSPLASTIC SYNDROME</a></li>
<li class="chapter" data-level="5.27" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#osteogenic-sarcoma"><i class="fa fa-check"></i><b>5.27</b> OSTEOGENIC SARCOMA</a></li>
<li class="chapter" data-level="5.28" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#ovarian-cancer-epithelial"><i class="fa fa-check"></i><b>5.28</b> OVARIAN CANCER (EPITHELIAL)</a></li>
<li class="chapter" data-level="5.29" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#ovarian-cancer-germ-cell"><i class="fa fa-check"></i><b>5.29</b> OVARIAN CANCER (GERM CELL)</a></li>
<li class="chapter" data-level="5.30" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#pancreatic-cancer"><i class="fa fa-check"></i><b>5.30</b> PANCREATIC CANCER</a></li>
<li class="chapter" data-level="5.31" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#prostate-cancer"><i class="fa fa-check"></i><b>5.31</b> PROSTATE CANCER</a></li>
<li class="chapter" data-level="5.32" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#renal-cell-cancer"><i class="fa fa-check"></i><b>5.32</b> RENAL CELL CANCER</a></li>
<li class="chapter" data-level="5.33" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#soft-tissue-sarcomas"><i class="fa fa-check"></i><b>5.33</b> SOFT TISSUE SARCOMAS</a></li>
<li class="chapter" data-level="5.34" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#testicular-cancer"><i class="fa fa-check"></i><b>5.34</b> TESTICULAR CANCER</a></li>
<li class="chapter" data-level="5.35" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#thymoma"><i class="fa fa-check"></i><b>5.35</b> THYMOMA</a></li>
<li class="chapter" data-level="5.36" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#thyroid-cancer"><i class="fa fa-check"></i><b>5.36</b> THYROID CANCER</a></li>
<li class="chapter" data-level="5.37" data-path="common-chemotherapy-regimens.html"><a href="common-chemotherapy-regimens.html#waldenströms-macroglobulinemia"><i class="fa fa-check"></i><b>5.37</b> WALDENSTRÖM’S MACROGLOBULINEMIA</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="common-terminology-criteria-for-adverse-events.html"><a href="common-terminology-criteria-for-adverse-events.html"><i class="fa fa-check"></i><b>6</b> Common Terminology Criteria for Adverse Events</a>
<ul>
<li class="chapter" data-level="6.1" data-path="common-terminology-criteria-for-adverse-events.html"><a href="common-terminology-criteria-for-adverse-events.html#ctcae-v5.0"><i class="fa fa-check"></i><b>6.1</b> CTCAE v5.0</a></li>
</ul></li>
<li><a href="part-ii-oncology.html#part-ii---oncology"><em>Part II - Oncology</em></a></li>
<li class="chapter" data-level="7" data-path="prostate-cancer-1.html"><a href="prostate-cancer-1.html"><i class="fa fa-check"></i><b>7</b> Prostate Cancer</a>
<ul>
<li class="chapter" data-level="7.1" data-path="prostate-cancer-1.html"><a href="prostate-cancer-1.html#staging-system-for-prostate-cancer"><i class="fa fa-check"></i><b>7.1</b> Staging System for Prostate Cancer</a></li>
<li class="chapter" data-level="7.2" data-path="prostate-cancer-1.html"><a href="prostate-cancer-1.html#diagnosis---prostate-cancer"><i class="fa fa-check"></i><b>7.2</b> Diagnosis - prostate cancer</a></li>
<li class="chapter" data-level="7.3" data-path="prostate-cancer-1.html"><a href="prostate-cancer-1.html#treatment---prostate-cancer"><i class="fa fa-check"></i><b>7.3</b> Treatment - prostate cancer</a></li>
<li class="chapter" data-level="7.4" data-path="prostate-cancer-1.html"><a href="prostate-cancer-1.html#principles-of-genetics---prostate-cancer"><i class="fa fa-check"></i><b>7.4</b> Principles of Genetics - prostate cancer</a></li>
<li class="chapter" data-level="7.5" data-path="prostate-cancer-1.html"><a href="prostate-cancer-1.html#principles-of-imaging---prostate-cancer"><i class="fa fa-check"></i><b>7.5</b> Principles of Imaging - prostate cancer</a></li>
<li class="chapter" data-level="7.6" data-path="prostate-cancer-1.html"><a href="prostate-cancer-1.html#principles-of-active-surveillance-and-observation"><i class="fa fa-check"></i><b>7.6</b> Principles of Active Surveillance and Observation</a></li>
<li class="chapter" data-level="7.7" data-path="prostate-cancer-1.html"><a href="prostate-cancer-1.html#principles-of-radiation-therapy"><i class="fa fa-check"></i><b>7.7</b> Principles of Radiation Therapy</a></li>
<li class="chapter" data-level="7.8" data-path="prostate-cancer-1.html"><a href="prostate-cancer-1.html#principles-of-surgery"><i class="fa fa-check"></i><b>7.8</b> Principles of Surgery</a></li>
<li class="chapter" data-level="7.9" data-path="prostate-cancer-1.html"><a href="prostate-cancer-1.html#principles-of-androgen-deprivation-therapy"><i class="fa fa-check"></i><b>7.9</b> Principles of Androgen Deprivation Therapy</a></li>
<li class="chapter" data-level="7.10" data-path="prostate-cancer-1.html"><a href="prostate-cancer-1.html#section"><i class="fa fa-check"></i><b>7.10</b> 　</a></li>
</ul></li>
<li><a href="part-iii-diabetes-mellitus.html#part-iii---diabetes-mellitus"><em>Part III - Diabetes Mellitus</em></a></li>
<li><a href="part-iv-geriatrics.html#part-iv---geriatrics"><em>Part IV - Geriatrics</em></a></li>
<li><a href="part-v-others.html#part-v---others"><em>Part V - Others</em></a></li>
<li class="chapter" data-level="8" data-path="icd-10-cm.html"><a href="icd-10-cm.html"><i class="fa fa-check"></i><b>8</b> ICD 10 CM</a>
<ul>
<li class="chapter" data-level="8.1" data-path="icd-10-cm.html"><a href="icd-10-cm.html#國際疾病分類第十版中英對照檢索"><i class="fa fa-check"></i><b>8.1</b> 國際疾病分類第十版中英對照檢索</a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="tfda-atc.html"><a href="tfda-atc.html"><i class="fa fa-check"></i><b>9</b> TFDA ATC</a>
<ul>
<li class="chapter" data-level="9.1" data-path="tfda-atc.html"><a href="tfda-atc.html#藥品藥理治療分類-atc-code"><i class="fa fa-check"></i><b>9.1</b> 藥品藥理治療分類 ATC Code</a></li>
</ul></li>
<li class="chapter" data-level="10" data-path="tfda-ahfsdi.html"><a href="tfda-ahfsdi.html"><i class="fa fa-check"></i><b>10</b> TFDA AHFS/DI</a>
<ul>
<li class="chapter" data-level="10.1" data-path="tfda-ahfsdi.html"><a href="tfda-ahfsdi.html#藥品藥理治療分類-ahfsdi-code"><i class="fa fa-check"></i><b>10.1</b> 藥品藥理治療分類 AHFS/DI Code</a></li>
</ul></li>
<li class="chapter" data-level="11" data-path="frequently-used-links.html"><a href="frequently-used-links.html"><i class="fa fa-check"></i><b>11</b> Frequently Used Links</a>
<ul>
<li class="chapter" data-level="11.1" data-path="frequently-used-links.html"><a href="frequently-used-links.html#醫藥參考"><i class="fa fa-check"></i><b>11.1</b> 醫藥參考</a></li>
<li class="chapter" data-level="11.2" data-path="frequently-used-links.html"><a href="frequently-used-links.html#醫藥文獻"><i class="fa fa-check"></i><b>11.2</b> 醫藥文獻</a></li>
<li class="chapter" data-level="11.3" data-path="frequently-used-links.html"><a href="frequently-used-links.html#藥物辨識"><i class="fa fa-check"></i><b>11.3</b> 藥物辨識</a></li>
<li class="chapter" data-level="11.4" data-path="frequently-used-links.html"><a href="frequently-used-links.html#藥品給付"><i class="fa fa-check"></i><b>11.4</b> 藥品給付</a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="memo.html"><a href="memo.html"><i class="fa fa-check"></i><b>12</b> Memo</a>
<ul>
<li class="chapter" data-level="12.1" data-path="memo.html"><a href="memo.html#daily-tasks"><i class="fa fa-check"></i><b>12.1</b> Daily Tasks</a></li>
<li class="chapter" data-level="12.2" data-path="memo.html"><a href="memo.html#print-medical-orders"><i class="fa fa-check"></i><b>12.2</b> Print Medical Orders</a></li>
<li class="chapter" data-level="12.3" data-path="memo.html"><a href="memo.html#brevity-codes"><i class="fa fa-check"></i><b>12.3</b> Brevity Codes</a></li>
</ul></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">　　　　</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="chemotherapy-dosage-based-on-renal-function" class="section level1" number="3">
<h1><span class="header-section-number">3</span> Chemotherapy Dosage Based on Renal Function</h1>
<div id="recommended-dose-reduction-for-renal-dysfunction" class="section level2" number="3.1">
<h2><span class="header-section-number">3.1</span> Recommended Dose Reduction for Renal Dysfunction</h2>
<div id="htmlwidget-9ca426f9e633d061010b" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-9ca426f9e633d061010b">{"x":{"filter":"top","filterHTML":"<tr>\n  <td><\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n    <\/div>\n  <\/td>\n<\/tr>","data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146"],["Abemaciclib","Acalabrutinib","Afatinib","Alectinib","Alemtuzumab","Altretamine","Aminoglutethimide","Anastrozole","Apalutamide","Arsenic trioxide","L-Asparaginase","Atezolizumab","Avelumab","Axicabtagene ciloleucel","Belinostat","Bendamustine","Bevacizumab","Bicalutamide","Bleomycin","Blinatumomab","Bosutinib","Brigatinib","Buserelin","Busulfan","Cabozantinib","Capecitabine","Carboplatin","Carfilzomib","Carmustine","Ceritinib","Cetuximab","Chlorambucil","Cisplatin","Cladribine","Clofarabine","Copanlisib","Cyclophosphamide","Cytarabine","Dacarbazine","Dactinomycin","Daratumumab","Dasatinib","Daunorubicin","Daunorubicin and","cytarabine liposome","Decitabine","Docetaxel","Doxorubicin","Doxorubicin liposome","Durvalumab","Elotuzumab","Enasidenib","Eribulin","Erlotinib","Estramustine","Etoposide","Etoposide phosphate","Everolimus","Floxuridine","Fludarabine","5-Fluorouracil","Flutamide","Gefitinib","Gemcitabine","Gemtuzumab","Goserelin","Hydroxyurea","Ibrutinib","Idarubicin","Ifosfamide","Imatinib","Inotuzumab","Interferon-alpha","Interleukin-2","Irinotecan","Irinotecan liposome","Isotretinoin","Ixabepilone","Ixazomib","Lapatinib","Lenalidomide","Lenvatinib","Leuprolide","Lomustine","Lutetium Lu 177 dotatate","Mechlorethamine","Megestrol acetate","Melphalan","6-Mercaptopurine","Methotrexate","Mitomycin-C","Mitotane","Mitoxantrone","Necitumumab","Nelarabine","Neratinib","Nilotinib","Nilutamide","Niraparib","Nivolumab","Obinutuzumab","Ofatumumab","Olaparib","Osimertinib","Oxaliplatin","Paclitaxel","Palbociclib","Panitumumab","Pazopanib","Pegasparaginase","Pembrolizumab","Pemetrexed","Pertuzumab","Pomalidomide","Ponatinib","Pralatrexate","Procarbazine","Ramucirumab","Regorafenib","Ribociclib","Rituximab","Rituximab and hyaluronidase human","Rucaparib","Sonidegib","Sorafenib","Streptozocin","Sunitinib","Tamoxifen","Temozolomide","Temsirolimus","Thalidomide","Thioguanine","Thiotepa","Tisagenlecleucel","Topotecan","Trabectedin","Trametinib","Trastuzumab","Tretinoin","Trifluridine/tipiracil","Venetoclax","Vinblastine","Vincristine","Vinorelbine","Vorinostat","Ziv-aflibercept"],["No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or in patients with end-stage renal disease.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or in patients with end-stage renal disease.","No dose reduction for mild renal dysfunction. Dose reduction may be necessary with moderate or severe renal dysfunction.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or in patients with end-stage renal disease.","N/A","N/A","N/A","No dose reduction is necessary.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or in patients with end-stage renal disease.","No formal recommendation for dose reduction in the presence of renal dysfunction. Dose reduction may be necessary.","Omit if CrCl <60 mL/min.","No dose reduction is necessary.","No dose reduction is necessary.","N/A","No dose reduction for mild or moderate renal dysfunction. Has not been studied in patients with CrCl <39 mL/min.","Omit if CrCl <30 mL/min.","N/A","No dose reduction is necessary.","No dose reduction if CrCl >50 mL/min. Reduce dose by 25% if CrCl 10-50 mL/min. Reduce dose by 50% if CrCl <10 mL/min.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in patients with severe renal dysfunction or in those with end-stage renal disease.","No dose reduction for mild renal dysfunction. Dose reduction is recommended in patients with moderate or severe renal dysfunction. Has not been studied in patients with end-stage renal disease.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in patients with severe renal dysfunction or in those with end-stage renal disease.","N/A","No dose reduction is necessary.","No dose reduction for mild or moderate renal dysfunction. Omit in the presence of severe renal dysfunction.","No dose reduction if CrCl >50 mL/min. Reduce dose by 25% if CrCl 30-50 mL/min. Omit if CrCl <30 mL/min.","No dose reduction if CrCl >60 mL/min. AUC dose is modi- fied according to CrCl.","No dose reduction is necessary.","Omit if CrCl <60 mL/min.","N/A","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction if CrCl >60 mL/min. Reduce dose by 50% if CrCl 30-60 mL/min. Omit if CrCl <30 mL/min.","No dose reduction if CrCl >50 mL/min. Reduce dose by 25% if CrCl 10-50 mL/min. Reduce dose by 50% if CrCl <10 mL/min.","No dose reduction if CrCl >60 mL/min. Reduce dose by 50% if CrCl 30-60 mL/min. Has not been studied in setting of severe renal dysfunction (CrCl < 30 mL/min) or in patients on dialysis.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or in patients with end-stage renal disease.","No dose reduction if CrCl >20 mL/min. Reduce dose by 25% if CrCl 10-20 mL/min. Reduce dose by 50% if CrCl <10 mL/min.","No formal recommendation for dose reduction in presence of renal dysfunction. Dose reduction may be necessary.","No formal recommendation for dose reduction in presence of renal dysfunction. Dose reduction may be necessary.","N/A","No dose reduction is necessary.","No dose reduction is necessary.","Reduce dose by 50% if serum creatinine >3.0 mg/dL.","No dose reduction for mild or moderate renal dysfunction.","Has not been studied in setting of severe renal dysfunction or in patients with end-stage renal disease.","N/A","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction, and dose reduction may be necessary.","No dose reduction is necessary.","No dose reduction if CrCl ≥30 mL/min.","No dose reduction for mild renal dysfunction. The dose should be reduced to 1.1 mg/m2 in setting of moderate or severe renal dysfunction.","No dose reduction is necessary.","N/A","No dose reduction if CrCl >50 mL/min. Reduce dose by 25% if CrCl 15-50 mL/min. Reduce dose by 50% if CrCl <15 mL/min.","No dose reduction if CrCl >50 mL/min. Reduce dose by 25% if CrCl 10-50 mL/min. Reduce dose by 50% if CrCl <10 mL/min.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction if CrCl >70 mL/min. Reduce dose by 20% if CrCl 30-70 mL/min. Omit if CrCl <30 mL/min.","No dose reduction is necessary.","N/A","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in patients with severe renal dysfunction or in those on dialysis.","No dose reduction is necessary.","Reduce dose by 50% if CrCl 10-50 mL/min. Reduce dose by 80% if CrCl <10 mL/min.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in patients with severe renal dysfunction or in those on dialysis.","No dose reduction is necessary.","No dose reduction if CrCl >60 mL/min. Reduce dose by 20% if CrCl 46-59 mL/min. Reduce dose by 25% if CrCl 31-45 mL/min. Reduce dose by 30% if CrCl <30 mL/min.","No dose reduction is necessary.","No dose reduction for mild, moderate, or severe renal dysfunction. Has not been studied in patients with end-stage renal disease or in those on dialysis.","No dose reduction is necessary.","Omit or discontinue if serum creatinine >4.5 mg/dL.","No dose reduction is necessary.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in patients with severe renal dysfunction or in those with end-stage renal disease.","N/A","No formal recommendation for dose reduction.","No dose reduction for mild or moderate renal dysfunction. Dose should be reduced in patients with severe renal dysfunction or in those with end-stage renal disease.","No dose reduction is necessary.","No formal recommendation for dose reduction. In the setting of moderate and severe renal dysfunction, dose reduction may be necessary.","No dose reduction for mild or moderate renal dysfunction. In severe renal dysfunction, the dose should be reduced to 14 mg PO daily for thyroid cancer and to 10 mg PO daily for renal cell cancer. Has not been studied in end-stage renal disease or in patients on dialysis.","N/A","Omit if CrCl <60 mL/min.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in patients with severe renal dysfunction or in those on dialysis.","N/A","N/A","No formal recommendation for dose reduction. However, use with caution in the presence of renal dysfunction.","No formal recommendation for dose reduction in presence of renal dysfunction. May need to adjust for renal dysfunction by either increasing the interval or decreasing the dose.","No dose reduction if CrCl >60 mL/min. Reduce by 50% if CrCl 30-60 mL/min. Omit if CrCl <30 mL/min.","No dose reduction if CrCl >60 mL/min. Reduce dose by 25% if CrCl 10-60 mL/min. Reduce dose by 50% if CrCl <10 mL/min.","N/A","No dose reduction is necessary.","No formal studies have been done in setting of renal dysfunction.","No formal recommendation for dose reduction. Dose reduction may be necessary in setting of moderate or severe renal dysfunction.","N/A","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or in patients with end-stage renal disease.","No dose reduction is necessary.","No dose reduction for mild or moderate dysfunction. Has not been studied in setting of severe renal dysfunction or in patients with end-stage renal disease.","N/A","No dose reduction for mild renal dysfunction. Dose should be reduced to 300 mg bid in presence of moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or end-stage renal disease.","No dose reduction for mild, moderate, and severe renal dysfunction. Has not been studied in end-stage renal disease.","No formal recommendation for dose reduction. Omit if CrCl <20 mL/min.","No dose reduction is necessary.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction.","No dose reduction is necessary.","No dose reduction is necessary.","N/A","No dose reduction is necessary.","No dose reduction is necessary when CrCl >45 mL/min. Omit if CrCL <45 mL/min.","No dose reduction for mild or moderate renal  dysfunction. No formal recommendation for dose reduction in the presence of severe renal dysfunction.","No dose reduction for patients with serum creatinine <3.0 mg/dL. Omit if serum creatinine >3.0 mg/dL.","No dose reduction for mild renal dysfunction. Dose reduction may be necessary in the setting of moderate or severe renal dysfunction.","No formal recommendation for dose reduction. Dose reduction may be necessary in the setting of moderate or severe renal dysfunction.","Omit if CrCl <30 mL/min.","N/A","No dose reduction for mild renal dysfunction. No formal recommendation for dose reduction in setting of moderate or severe renal dysfunction.","N/A","N/A","N/A","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or in patients with end-stage renal disease.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or in patients with end-stage renal disease.","No dose reduction is necessary.","No dose reduction if CrCl >60 mL/min. Reduce dose by 25% if CrCl 10-50 mL/min. Reduce dose by 50-75% if CrCl <10 mL/min.","N/A","No dose reduction is necessary.","N/A","No dose reduction is necessary.","No formal recommendation for dose reduction in presence of renal dysfunction.","N/A","No formal recommendation for dose reduction in presence of renal dysfunction.","N/A","No dose reduction is necessary if CrCl >40 mL/min. Reduce dose by 50% if CrCl 20-39 mL/min. Omit if CrCl <20 mL/min.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or in patients with end-stage renal disease.","No dose reduction for mild and moderate renal dysfunction. No formal recommendation for dose reduction in setting of severe renal dysfunction.","N/A","Give a maximum of 25 mg/m2 in the presence of renal dysfunction.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or in end-stage renal disease.","No dose reduction for mild or moderate renal dysfunction. Has not been studied in setting of severe renal dysfunction or in end-stage renal disease.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction is necessary.","N/A"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Recommended Dose Reduction for Renal Dysfunction<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"pageLength":10,"lengthMenu":[10,100,1000],"searchHighlight":true,"search":{"regex":false,"caseInsensitive":true},"autoWidth":true,"order":[],"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"orderCellsTop":true}},"evals":[],"jsHooks":[]}</script>
<ul>
<li>CrCl: creatinine clearance</li>
<li>N/A: not available</li>
</ul>

</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="chemotherapy-dosage-based-on-hepatic-function.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="dialysis-of-chemotherapy-drugs.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
